In breast cancer, it has been shown that cells positive for CD44 and negative for CD24 are more aggressive, invasive, and tumorigenic1; and forced expression of HER2, in otherwise HER2-negative breast cancer cells, has been shown to enhance resistance to radiation therapy2. This evidence concerns the gene ERBB2 and breast carcinoma.